Zymeworks Inc. Archives | Be Korea-savvy

Home / Posts tagged Zymeworks Inc.

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, [...]

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancer ZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster [...]

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 21, 2025 (Korea Bizwire) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare [...]

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation Novel bispecific design shows promising potential manufacturability and stability to support high dosing concentration and subcutaneous administration Regulatory filing to support Phase 1 studies expected in 2H-2026 VANCOUVER, British Columbia, May [...]

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional [...]

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

VANCOUVER, British Columbia, Feb. 26, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achievement of a $14 million cash research milestone from GSK associated with a [...]

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms VANCOUVER, British Columbia, Sept. 18, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat cancers and [...]